K2 Principal Fund, L.P. Kodiak Sciences Inc. Transaction History
K2 Principal Fund, L.P.
- $210 Million
- Q3 2024
Shares
1 transactions
Others Institutions Holding KOD
# of Institutions
98Shares Held
39MCall Options Held
6.5KPut Options Held
5.8K-
Baker Bros. Advisors LP New York, NY17.3MShares$151 Million0.48% of portfolio
-
Black Rock Inc. New York, NY3.85MShares$33.7 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.95MShares$17.1 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.69MShares$14.7 Million0.0% of portfolio
-
Iconiq Capital, LLC San Francisco, CA1.02MShares$8.9 Million0.06% of portfolio
About Kodiak Sciences Inc.
- Ticker KOD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,040,200
- Market Cap $455M
- Description
- Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...